PD-L1 positivity in tumor cells was also significantly linked to favorable tumor phenotype and prolonged survival in NST carcinomas that were all treated before 2019, when checkpoint inhibitors were approved for use in breast cancer patients in Germany. This evidence concerns the gene CD274 and neoplasm.